Synthetic Peptide
CALHM1 Synthetic Peptide, PEP-1009, from Invitrogen.
Alzheimers disease (AD) is a progressive neurodegenerative disorder characterized by a massive loss of neurons in several brain regions and by the presence of senile plaques comprised of aggregated amyloid-beta (Abeta) peptides produced by the endoproteolysis of the amyloid precursor protein (APP). The calcium homeostasis modulator 1 (CALHM1) is a recently identified multipass transmembrane glycoprotein that controls cytosolic Ca2+ concentration and Abeta levels. While some studies suggest CALHM1 is significantly associated with risk of AD, other reports suggest there is no link. CALHM1 has been suggested to modulate the Ca2+-dependent proteolytic process of APP through controlling the level of cytosolic Ca2+.
| Marque | Invitrogen |
|---|---|
| Réf. B-LABO | BL-RE-175654 |
| Réf. fabricant | 15255009 |
| Gene ID (Entrez) | 255022 |
| Espèces | Human |
| Méthode de purification | purified |
| Numéro d’adhésion | Q8IU99 |
| Nom usuel | Human CALHM1 |
| Concentration | 200 μg/mL |
| Contenu et stockage | -20°C |
| Format | Liquid |
| Formule | PBS with 0.1% BSA and 0.02% sodium azide; pH 7.2 |
| À utiliser avec (application) | Blocking Assay, Control |
| Symbole de gène(s) | CALHM1 |
| Lyophilisé | No |
| Conservateur | 0.02% sodium azide |
| Type de produit | Peptide |
| Quantité | 50 μg |
| État réglementaire | RUO - research use only |
| Tampon de stockage | PBS |
